Результаты поиска

Electroacupuncture Relieves Suppression of Autophagy in Interstitial Cells of Cajal of Diabetic Gastroparesis Rats.

BACKGROUND: The incidence of diabetic gastroparesis (DGP) is mainly blamed to abnormity of interstitial cells of Cajal (ICCs). Autophagy cou … c gastroparesis group (DGP, 10), GDP rats with electroacupuncture group (EA, 10), and GDP rats with metoclopramide group (MP, 10). When the intervention was completed, blood glucose was measured by ONE TOUCH glucometer and gastrointestinal propulsive rate was detected through measuring optical density. Autophagosomes were observed under transmission electron mic …

Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States.

Renal impairment is a common complication of multiple myeloma and deterioration in renal function or renal failure may complicate clinical management. This retrospective study in patients with multiple myeloma using an electronic medical records database was designed to estimate the prevalence of renal impairment (single occurrence of estimated glomerular filtration rate [eGFR] 2 on or after multiple myeloma diagnosis) and chronic kidney disease (at least two eGFR values 2 after multiple myeloma diagnosis that had been measured at least 90 days apart), and to describe the use of nephrotoxic ag

Совпадение в полном тексте источника
… The use of nephrotoxic agents including core anti‐myeloma therapies (doxorubicin, cisplatin, and epirubicin) and supportive care (metoclopramide; intravenous bisphosphonates, zoledronic acid or pamidronate) was described before and after either the first lowest post diagnosis eGFR value (in the case … Usage of nephrotoxic medications (doxorubicin, metoclopramide, cisplatin, epirubicin, intravenous bisphosphonates) In the 5334 patients with renal impairment, the use of nephrotoxic agents or specifically bisphosphonates did not notably change from before the lowest eGFR value (median time from diagnosis …

Menorrhagia due to uterine amyloidosis in familial Mediterranean fever: case-based review.

Amyloidosis is described by the deposition of misfolded proteins in the tissues. Amyloidoses are classified into two as systemic and localized. Out of the systemic forms, AL (light chain) amyloidosis is the most prevalent type; however, amyloid A (AA) amyloidosis is more frequently encountered in the rheumatology practice. AA amyloidosis stands out as a major complication of familial Mediterranean fever (FMF). Splenic and renal involvement is more likely in FMF-associated systemic amyloidosis. The involvement of thyroid and adrenal glands has also been described, although infrequently. Amyloid

Совпадение в полном тексте источника
… Urinalysis: + 3 protein Ferritin: 201 ng/mL 24-h urine proteinuria: 3.9 g/day Total protein: 5.92 Albumin: 3.54 Potassium: 6.08 mEq/L – Total protein: 7.58 Albumin: 4.4 24-h urine proteinuria: 7 g/day Treatments Colchicine Iron tablet Colchicine Colchicine Colchicine Colchicine Proton pump inhibitor Metoclopramide … protein Ferritin: 201 ng/mL 24-h urine proteinuria: 3.9 g/day | Total protein: 5.92 Albumin: 3.54 Potassium: 6.08 mEq/L | – | Total protein: 7.58 Albumin: 4.4 24-h urine proteinuria: 7 g/day Treatments | Colchicine Iron tablet | Colchicine | Colchicine | Colchicine | Colchicine Proton pump inhibitor Metoclopramide …

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

PURPOSE: This review is an update of the MASCC/ESMO 2015 recommendations for the prophylaxis of acute and delayed nausea and vomiting induced by multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. METHODS: A systematic literature search was conducted using PubMed from June 1, 2015, through February 1, 2023. RESULTS: We identified 56 references (16 were duplications or invalid), leaving 40 manuscripts for this search. The panel classified level I evidence (three manuscripts) and level II evidence (14 manuscripts). High-dose chemotherapy and stem cell trans

Совпадение в полном тексте источника
… A second search consisted of the following keywords: (ondansetron OR granisetron OR dolasetron OR tropisetron, OR palonosetron OR ramosetron OR azasetron or metoclopramide OR domperidone OR metopimazine OR prochlorperazine OR olanzapine OR aprepitant OR fosaprepitant OR netupitant OR fosnetupitant OR … stem cell transplant | 5-HT 3 -RA + Dex + Apr (2) | I/A Breakthrough | Olz (3) | II/B Additionally, a search was performed for breakthrough nausea and vomiting utilizing the following keywords: (ondansetron OR granisetron OR dolasetron OR tropisetron, OR palonosetron OR ramosetron OR azasetron or metoclopramide …

AGA Clinical Practice Update on Pregnancy-Related Gastrointestinal and Liver Disease: Expert Review.

DESCRIPTION: The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update is to review the availabl … of symptom control with vitamin B6 and doxylamine, hydration, and adequate nutrition; ondansetron, metoclopramide, promethazine, and intravenous glucocorticoids may be required in moderate to severe cases. BEST PRACTICE ADVICE 5: Constipation in pregnant persons may result from hormonal, medication-related, and physiological changes. Treatment options include d …

Amyloidosis for the Gastroenterologist: A Comprehensive Systematic Review of Diagnosis and Management of Gastrointestinal Manifestations.

BackgroundAmyloidosis is a rare, multisystem disorder characterized by extracellular deposition of misfolded protein fibrils. Gastrointestinal (GI) amyloidosis is uncommon but under-recognized due to nonspecific symptoms, but early diagnosis is critical to improve quality of life and prognosis. This comprehensive systematic review aimed to summarize current literature on GI and hepatic manifestations of amyloidosis, highlighting diagnostic and management strategies across the major subtypes of amyloidosis, in particular AL (immunoglobulin light chain), ATTR (transthyretin), and AA (serum amylo

Совпадение в полном тексте источника
… In AL amyloidosis, domperidone (up to 20 mg every 6 h before meals) and metoclopramide are recommended [ 73 , 96 , 97 ]. In ATTRv amyloidosis, erythromycin (50–250 mg two to three times daily) or domperidone (10 mg twice daily, 5 min before meals) is preferred [ 3 , 98 ]. … For prolonged treatment, domperidone is recommended long‐term, while metoclopramide (IM or IV) may be used for acute attacks or recurrent vomiting [ 25 , 98 ]. …

Antitumoral Agent-Induced Constipation: A Systematic Review.

BackgroundConstipation is a common symptom in patients receiving antitumoral treatment. The mechanisms underlying antitumoral agent-induced constipation (ATAIC) are poorly defined. This systematic review aimed to analyze and synthesize the available information related to the prevalence, etiology, and treatment of ATAIC.MethodsA systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines was conducted. The review included human studies written in English, French, or Spanish involving patients with cancer and containing information abou

Совпадение в полном тексте источника
… The case report explained the benefits of metoclopramide in a patient with ileus secondary to vincristine [ 6 ]. The main contents are explained in Table 4 . 4. Discussion Constipation is a feared and frequently reported symptom in patients with cancer treated with antitumoral agents. … Metoclopramide is ineffective. …

Stimulation of the wrist acupuncture point PC6 for preventing postoperative nausea and vomiting.

BACKGROUND: Postoperative nausea and vomiting (PONV) are common complications following surgery and anaesthesia. Antiemetic drugs are only p … rimary outcomes.PC6 acupoint stimulation was compared with six different types of antiemetic drugs (metoclopramide, cyclizine, prochlorperazine, droperidol. ondansetron and dexamethasone). There was no difference between PC6 acupoint stimulation and antiemetic drugs in the incidence of nausea (RR 0.91, 95% CI 0.75 to 1.10; 14 trials, 1332 participants), vomiting …

Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists.

PurposeTo discuss new therapeutic strategies for chemotherapy-induced nausea and vomiting (CINV) involving 5-hydroxytryptamine type 3 (5HT3)-receptor antagonists (RAs).SummaryCINV remains poorly controlled in patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC); nausea and delayed-phase CINV (24-120 hours after chemotherapy) are the most difficult to control. National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) antiemesis-guideline recommendations for HEC include a four-drug regimen (5HT3 RA, neurokinin 1 [

Совпадение в полном тексте источника
… Olanzapine may be added if it was not part of the initial antiemetic regimen, and other dopamine antagonists (eg, metoclopramide, phenothiazines) may also be considered. 7 , 19 Multiple concurrent antiemetics may be required and administered continuously, rather than as needed. … If a combination of a 5HT 3 RA and dexamethasone with or without an NK 1 RA has previously been used, other options of different classes include olanzapine, benzodiazepine, or metoclopramide. 7 , 19 The use of 5HT 3 RAs in the breakthrough setting is based on their efficacy as prophylactic antiemetics …

Эффективность интенсивной антиэпидемиологической терапии, включая оланзапин у нескольких пациентов миэломы, лечившихся высокодозированными мелфаланами с аутологической трансплантацией стволовых клеток.

ЦЕЛЬ: Кондиционирование с использованием высокодозированного мелфалана (MEL), за которым следует аутологическая трансплантация стволовых клеток (ASCT), является стандартным методом лечения множественной миеломы (MM). Оптимальный режим предотвращения тошноты и рвоты, вызванных химиотерапией, не ясен. Мы стремились ретроспективно оценить антиеметический эффект и безопасность four- интенсивный наркологический режим, включая оланзапин (ОЛА) на CINV у пациентов MM, получающих MEL/ASCT. МЕТОДЫ: МЕЛ200 мг/м2) в дневное время 1, за которым следует ASCT в день 3. Пациенты были отнесены к стандартной гр

Совпадение в полном тексте источника
… Rescue medication (metoclopramide [5 mg p.o.] or metoclopramide [10 mg i.v.]) for breakthrough CINV was provided at the physician’s discretion. …

Acute kidney injury manifesting as renal tubular acidosis with proximal and distal renal tubular dysfunction in a dog with acute pancreatitis.

OBJECTIVE: To describe the clinical presentation and management of a critically ill dog with profound renal tubular acidosis (RTA) with proximal and distal renal tubular dysfunction. CASE SUMMARY: A 3-year-old neutered female Border Terrier was presented with frequent regurgitation resulting from acute pancreatitis with severe ileus. Venous acid-base analysis and complete urinalysis confirmed the presence of normal anion gap metabolic acidosis with inappropriately alkaline urine (pH 8), consistent with distal RTA. Urinalysis, urine amino acids, and urinary fractional excretion of electrolytes

Совпадение в полном тексте источника
… Hartmann's solution b was administered intravenously at 6 ml/kg/h with 15 mmol/L potassium chloride. m Prokinetic therapy with metoclopramide n (2 mg/kg/day, IV, as a constant rate infusion) and erythromycin o (1 mg/kg, IV, q 8 h) was used for treatment of ileus. … Metoclopramide 5 mg/ml injection, Hameln Pharmaceuticals Limited, Gloucester Business Park, Gloucester. Erythromycin lactobionate, 1 g powder for solution for infusion, Advanz Pharma, London, UK. Omeprazole, 40 mg powder for solution for infusion, Bowmed Ibisqus Limited, Chirk, Wrexham. …

Tumoral parkinsonism-Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment.

INTRODUCTION: Secondary tumoral parkinsonism is a rare phenomenon that develops as a direct or indirect result of brain neoplasms or related conditions. OBJECTIVES: The first objective was to explore to what extent brain neoplasms, cavernomas, cysts, paraneoplastic syndromes (PNSs), and oncological treatment methods cause parkinsonism. The second objective was to investigate the effect of dopaminergic therapy on the symptomatology in patients with tumoral parkinsonism. METHODS: A systematic literature review was conducted in the databases PubMed and Embase. Search terms like "secondary parki

Совпадение в полном тексте источника
… Metoclopramide is a well‐known cause to drug‐induced parkinsonism. Oncological parkinsonism in children It is extremely rare for idiopathic PD to develop in children, and this type, which is referred to as juvenile parkinsonism, is often associated with specific, high‐risk genes. … Parkinsonism following i.v. administration of high‐dose metoclopramide used as an antiemetic agent during cancer chemotherapy . Cancer Treatment Reports , 69 ( 3 ), 341 – 342 . 4038919 McMahan , S. A. , & Galvez , N. ( 2015 ). Meningioma presenting as Parkinsonism . …

A comprehensive evaluation of potentially significant drug-drug, drug-herb, and drug-food interactions among cancer patients receiving anticancer drugs.

IntroductionDuring the cancer treatment path, cancer patients use numerous drugs, including anticancer, supportive, and other prescribed medications, along with herbs and certain products. This puts them at risk of significant drug interactions (DIs). This study describes DIs in cancer patients and their prevalence and predictors.MethodsA cross-sectional study design was used to achieve the study objectives. The study was carried out in two centers in the northern West Bank, Palestine. The Lexicomp® Drug Interactions tool (Lexi-Comp, Hudson OH, USA) was applied to check the potential DIs. In a

Совпадение в полном тексте источника
… However, combinations that should be avoided ‘X’ were Doxorubicin/Aprepitant ( n = 20) and Promethazine/Metoclopramide ( n = 6). … For instance, Promethazine/Metoclopramide is one of the interactions to be avoided; the probable mechanism for this interaction has been reported as QTc interval prolongation. …

Оценка иглоукалывания и аурикулотерапии при борьбе с тошнотой и рвотой, вызванной химиотерапией: экспериментальное исследование.

ЦЕЛЬ: Оценка эффективности иглоукалывания и аурикулотерапии в деле уменьшения тошноты, вызванной химиотерапией, и рвоты у больных раком, по сравнению с антиэметическим протоколом. МЕТОД: Пилотное исследование прагматического two- Клинические испытания с применением огнестрельного оружия: группа иглоукалывания получила системную иглоукалывание, аурикулотерапию и антиеметический протокол; контрольная группа использовала антиеметический протокол. Образец состоял из: 42 больные раком желудочно-кишечной системы или множественной миеломой. Результаты были оценены с помощью инструмента химиотерапии п

Совпадение в полном тексте источника
… The occurrence of CINV was similar in both groups ( Table 3 ), as well as the use of antiemetics for nausea: Ondansetron hydrochloride, 16.7% (n = 3) of patients in GACA and 16.7% (n = 4) in CG; Dimenhydrinate, 11.1% (n = 2) of patients in GACA and 4.2% (n = 1) in CG; Metoclopramide hydrochloride, 27.8% … Patients in both groups used medication for vomiting: Ondansetron hydrochloride, 22.2% (n = 4) of patients in GACA and 8.3% (n = 2) in CG; Dimenhydrinate, 4.2% (n = 1) of patients in the CG; Metoclopramide hydrochloride, 11.1% (n = 2) of patients in GACA and 8.3% (n = 2) in CG. …

Multidisciplinary supportive care in systemic light chain amyloidosis.

The immunoglobulin light-chain amyloidosis is a multisystemic disease which manifests by damage to the vital organs by light chain-derived amyloid fibril. Traditionally, the treatment has been directed to the underlying plasma cell clone with or without high dose chemotherapy followed by autologous stem cell transplantation using melphalan based conditioning. Now with the approval of highly tolerable anti-CD38 monoclonal antibody daratumumab based anti-plasma cell therapy in 2021, high rates of hematologic complete responses are possible even in patients who are otherwise deemed not a candidat

Совпадение в полном тексте источника
… Peripheral neuropathy | Gabapentin, pregabalin are mainstay of therapy, SSRI can be useful, amitriptyline and nortriptyline should be avoided due to anti-cholinergic side effects Malnutrition | Adequate calorie and protein intake is important, all patients should have a nutritional plan Constipation | Metoclopramide … Treatment and supportive care In patients with motility disturbances, metoclopramide or loperamide can be used for constipation and diarrhea respectively. In patients with concurrent cardiac amyloidosis, QT prolongation should be considered. …

Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy.

IntroductionThe second-generation 5-hydroxytryptamine-3 (5-HT3) receptor antagonist palonosetron is effective in the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with highly and moderately emetogenic chemotherapy (HEC and MEC, respectively). In addition, palonosetron has been the first and, at present, the only 5-HT3 receptor antagonist to have a specific indication for the prevention of delayed CINV associated with MEC. The unique pharmacology of this antagonist is thought to partly explain its improved efficacy against delayed symptoms.AimsTo review the evidence u

Совпадение в полном тексте источника
… Another double-blind, randomized, Phase III trial evaluated the superiority of the combination of aprepitant and dexamethasone compared to metoclopramide plus dexamethasone in the prevention of delayed emesis in patients receiving cisplatin (single dose of ≥ 50 mg/m 2 ). 5 All patients received on day … combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose ranging pivotal trial Ann Oncol 2014 25 7 1340 1346 24608196 10.1093/annonc/mdu110 PMC4071755 5 Roila F Ruggeri B Ballatori E Aprepitant versus metoclopramide …

A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation.

BACKGROUND Approximately 10% to 15% of patients with multiple myeloma (MM) are diagnosed with high-risk disease and have poor prognosis. Clinical trial data supports the combined use of selinexor, bortezomib, and dexamethasone (XVd) for treatment of patients with MM who have received at least 1 prior therapy. Information on the efficacy of XVd and of subsequent allogeneic stem cell transplantation (SCT) in heavily pretreated patients with high-risk MM is limited. CASE REPORT We present a case of a 58-year-old woman with high-risk MM (revised International Staging System Stage III; serum ß₂-mic

Совпадение в полном тексте источника
… Prevention of nausea may be explained by the fact that according to the selinexor best clinical practice recommendations [ 17 ], the patient received 2 prophylactic anti-emetics: granisetron and metoclopramide. …

Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT).

Cancer patients have an increased risk of developing venous thromboembolic events. Anticoagulation management includes prophylactic or therapeutic doses of low molecular weight heparins (LMWHs) or direct oral anticoagulants (DOACs). However, the management of thrombosis in patients with cancer is complex due to various individual and disease-related factors, including drug-drug interactions (DDIs). Furthermore, DDIs may impact both, cancer and venous thrombosis, treatment effectiveness and safety; their relevance is highlighted by the advances in cancer therapeutics. Given that these new oncol

Совпадение в полном тексте источника
… Substrate No 77% Levofloxacin Moderate inhibitor and substrate No No 30-40% Doxycycline Moderate inhibitor and substrate No No 82-93% Erythromycin Strong inhibitor and substrate Strong inhibitor and substrate No No Antiemetic drugs Ondansetron Substrate Substrate No 70-76% Palonosetron Substrate No No 62% Metoclopramide … inhibitor and substrate | No | No | 30-40% Doxycycline | Moderate inhibitor and substrate | No | No | 82-93% Erythromycin | Strong inhibitor and substrate | Strong inhibitor and substrate | No | No Antiemetic drugs | Ondansetron | Substrate | Substrate | No | 70-76% Palonosetron | Substrate | No | No | 62% Metoclopramide …

Длительное использование цинка для дисгейзии, вызывающее нехватку меди.

Цинк является микроэлементом, необходимым для восприятия вкуса и может быть прописан для дисгейзии у больных раком, проходящих лечение. Однако чрезмерное потребление цинка может привести к дефициту меди, который, скорее всего, недооценивается и может представлять собой усталость, тошноту, анемию и миэлопатию. КИСЛОТА: Пациент в 70-летнем возрасте с несколькими миэломой и гастропарезом, принимающий добавки цинка для лечения дисгейсии в прошлом. 2 Годы, порожденные общей усталостью, головокружением, тошнотой, нейтрализмом, анемией, походом, а также ухудшением онемения и покалыванием в нижних кон

Совпадение в полном тексте источника
… He was advised to increase laxatives and take metoclopramide 5 mg three times daily for nausea and early satiety. …